RPG Life Sciences has announced that its wholly owned subsidiary, RPG Active Pharma (RPGAP), has entered into a Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (API) and intermediates business undertaking of Raghava Life Sciences. The acquisition will be completed on a going-concern basis through a slump sale for a consideration of up to INR 135 crore, subject to customary closing conditions and regulatory approvals.

The transaction forms part of RPGAP’s buy-and-build strategy aimed at strengthening organic growth and establishing an integrated, scaled and API-focused business. Following its recent acquisition of Actis Generics, the deal will further expand RPGAP’s manufacturing footprint, product portfolio, regulatory capabilities and customer access across domestic and international markets.

Raghava Life Sciences operates an API manufacturing facility near Hyderabad spread across approximately nine acres, with around 300 KL of installed capacity and a dedicated research and development setup. The facility holds WHO-GMP and EU-GMP approvals and has received significant investment towards capacity expansion in recent years. Its manufacturing infrastructure, chemistry capabilities and established regulatory credentials are expected to provide RPGAP with an expanded manufacturing base.

The business has developed a portfolio comprising 22 commercialised APIs and seven development-stage assets across therapeutic areas including diabetes, cardiovascular, Central Nervous System (CNS) and other segments. The portfolio includes commercially attractive molecules and is supported by international regulatory credentials such as Certificates of Suitability (CEP), EU Written Confirmation and KDMF approvals.

RPGAP expects to unlock synergies across the Raghava acquisition, Actis Generics and its existing network through backward integration, improved capacity utilisation, cost optimisation and selected product transfers. The combined platform is also expected to benefit from enhanced business development, broader market access, deeper customer coverage and focused portfolio execution.

The acquisition will be funded in line with the recent equity raise announced by RPGAP. The company expects the transaction to strengthen its cost competitiveness, accelerate portfolio expansion and improve operating leverage over time.

Commenting on the acquisition, Ashok Nair, Managing Director, RPG Life Sciences, said the transaction brings together a high-quality manufacturing asset, a broad commercial API portfolio, established regulatory credentials and strong customer relationships. He added that integrating the asset with RPGAP’s existing operations would create opportunities to improve capacity utilisation and strengthen commercialisation.

Lohith Ponguleti, Managing Director, Raghava Life Sciences, said the company’s integration with RPG would support its next phase of growth. He highlighted Raghava’s EU-GMP approved facility, technical capabilities and portfolio as a strong foundation for further expansion across domestic and international markets.

The acquisition marks another step in RPGAP’s strategy to build a larger and more integrated API platform, combining manufacturing capabilities, regulatory strength and a broader product portfolio to capture opportunities in the growing global API market.